Number of Credits: 1 CME Credit
After completing this course, the participant should be able to:
Lyndon M. Hill, MD
Professor Obstetrics and Gynecology
Medical Director Ultrasound
Magee Women's Hospital
The Institute for Advanced Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Institute for Advanced Medical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
These credits are accepted by the American Registry for Diagnostic Medical Sonography (ARDMS).
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board or other credentialing organization.
Physicians, sonographers and others who perform and/or interpret obstetrical ultrasound.
In order to complete this program you must have a computer with a recent browser version. You must also have the capability to display and print PDF files in order to view and print out your certificate. (Note: Your CME certificate is stored in your account and is available at any time.)
For any questions or problems concerning this program or for problems related to the printing of the certificate, please contact IAME at 802-824-4433 or firstname.lastname@example.org.
This activity is designed to be completed within the time designated. To successfully earn credit, participants must complete the activity during the valid credit period. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.
Follow these steps to earn CME credit:
Your CME credits will be archived in the account you create and can be accessed at any time.
Estimated Time for Completion: approximately 1 hour
Date of Release: July 1, 2011
Date of Most Recent Review: May 20, 2018
Expiration Date: May 20, 2021
In compliance with the Essentials and Standards of the ACCME, the author of this CME tutorial is required to disclose any significant financial or other relationships they may have with commercial interests.
Dr. Lyndon Hill discloses no financial interests with commercial interests.
No one at IAME who had control over the planning or content of this activity has relationships with commercial interests.
The urinary and genital systems develop from a common mesodermal ridge on the posterior abdominal wall. The 3 primordia of the definitive kidney (pronephros, meosonephros, and metanephros) develop sequentially; not only in time, but also in location. The pronephros arises cranially, the mesonephros in the mid-abdomen, and the metanephros caudally. The metanephros, or permanent kidney, begins to develop when the ureteric bud connects with the metanephros. The ureteric bud divides into two diverticula that eventually become major and minor calyces, as well as the remainder of the collecting system. The metanephric cap differentiates into the functioning units of the kidney or nephrons. The functioning nephrons continue to increase in number during prenatal development. Additional nephrons do not form after birth. As noted above, the metanephros is located within the pelvis. The apparent "ascent" of the kidneys is due to the rapid growth of the lumbar and sacral regions. Because of its change in location, the kidneys are vascularized by successively higher branches from the aorta.
The cloaca is separated by the urorectal septum into the urogenital sinus and anorectal canal. By week 7 the ureters open separately and directly into the bladder that has evolved from the urogenital sinus.
The production of urine begins by the 8th menstrual week as a plasma filtrate. The onset of renal tubular function is around 14 weeks. Urinary output is 5 ml/hr at 20 weeks' gestation and increases to 50 ml/hr by 40 weeks1.
Between 10-14 weeks' gestation an enlarged bladder with a diameter of 7-15 mm (Fig. 1) is associated with a 25% risk of aneuploidy. When the bladder diameter is > 15 mm, progressive obstructive uropathy invariably results2.
Pyelectasis refers to isolated dilatation of the renal pelves (Fig. 2) and is likely physiologic in origin, but may be due to ureteropelvic junction obstruction or reflux.
Transient upper urinary tract dilatation may be due to the slow canalization of the excretory system or delayed maturation of the urological junctions3.
The incidence of 2nd trimester pyelectasis varies with one's definition of a dilated renal pelvis, but is generally between 2%3,4 and 4.6%5. The average diameter of the renal pelvis is gestational age dependent. Therefore, it is a continuous, rather than categorical, variable. As a result, any single value for 2nd trimester pyelectasis is a compromise and will have a poor sensitivity and specificity for predicting subsequent neonatal obstruction. Dilatation into the caliceal system (Fig. 3) may also be physiologic, but increases the likelihood of obstruction or reflux.
In the 2nd trimester the antero-posterior dimension of the renal pelvis in autopsied kidneys of fetus without renal disease is 3.61 mm and 3.51 mm on the right, and 3.58 mm and 3.41 mm on the left for males and females, respectively6.
Several authors have concluded that a renal pelvis transverse dimension in the 2nd trimester > 5 mm2,6,7 and > 7 mm in the 3rd trimester2,8 require follow up for possible hypdronephrosis. While a lower threshold would be more sensitive in detecting postnatal obstruction, the false positive rate is higher. As one would expect, the likelihood of postnatal pathology increases from mild (11.9%) to moderate (45.1%) to severe (84.3%) pyelectasis. In some cases of severe obstruction, renal pelvis dilatation is not evident until after 24 weeks' gestation9.
The current definitions of pyelectasis in the 2nd and 3rd trimester are outlined in Table I. During the antenatal period approximately 80% of pyelectasis is mild, 15% moderate, and 5% severe1. After the detection of 2nd trimester pyelectasis, a follow up examination in the 3rd trimester with a stable or reduced renal pelvis diameter generally indicates eventual spontaneous resolution. Neonatal resolution of persistent antenatal pyelectasis is felt to be secondary to resolution of ureteral kinks and/or folds1.
Maternal hydration influences fetal urine flow rate and renal pelvis diameter. Hence, the ingestion of 48 ounces of water prior to an examination results in an increased prevalence of pyelectasis10.
Fetal bladder distension can affect the size of the renal pelves. If pyelectasis is detected, a repeat measurement with an empty fetal bladder should be obtained to confirm the finding. In one study 53% of fetuses with pyelectasis and a full bladder had normal renal pelves with bladder emptying11.
Pyelectasis tends to resolve or improve in 80% of cases1.
The male/female ratio for fetal pyelectasis is 2:112,13,14. The presence of fetal pyelectasis in one pregnancy increases the likelihood of detection in a subsequent sibling1.
The delineation of pyelectasis into three groups (Table I) can help with the development of a neonatal management scheme. Infants with severe renal pelvis dilatation in the 3rd trimester should undergo postnatal diagnostic testing and indicated treatment. While patients with moderate pyelectasis have a high prevalence of uropathy, they rarely require surgery and pyelectasis may resolve spontaneously. The majority of patients with mild pyelectasis do not have significant neonatal findings. The latter two groups (mild and moderate) can be followed for recurrent urinary tract infections or progressive pyelectasis as an indicator that additional testing is required1,15.
|Second Trimester||Third Trimester|
|Derived from Nguyen HT et al. J Pediatr Urol 2010;6:212.|
Calyceal dilatation is an important additional finding with pyelectasis that significantly increases the likelihodd of postnatal surgery and renal compromise5. Moderate to severe calyceal dilatation is clearly abnormal and will generally required neonatal surgery16.
A 2nd trimester antero-posterior renal pelvis diameter > 4.0 mm (Fig. 2) is considered a soft sonographic marker for trisomy 2117,18. Despite the higher prevalence in males, gender does not affect the association with fetal trisomies. Hence, counseling with respect to the risk of trimsomy can be gendered indepent14.
Ureteropelvic junction obstruction has an incidence of 1 in 2,000 livebirths19,20. 90% of cases are unilateral; males are more commonly affected. Extraluminal UPJ is due to a fibrous band or an aberrant vessel. Hence, the secondary obstruction may be intermittent. Luminal causes of UPJ are more common and are due to a build up of collagen and muscular fibers at the posterior urethral junction3. The presence of a valve or ureteral polyp are examples of intraluminal etiologies of UPJ.
25% of UPJ obstructions have other associated urologic abnormalities, including renal dysplasia, renal agenesis, and vesico-ureteral reflux21. 12% may have extra-renal anomalies22.
Hydronephrosis by definition indicates renal obstruction. Hence, this term can only be used with certainty after an appropriate neonatal evaluation. As the severity of obstruction worsens, the calyces change in appearance from dilated (Fig. 3) to rounded (Fig. 4) to absent (Fig. 5)16.
A renal parenchyma thickness < 3 mm would be considered significantly thinned (Fig. 6). This does not always equate with poor renal function. With the relief of an obstruction in the neonatal period, the parenchymal dimension may return to a more normal diameter and renal function may also be normal5.
When upper tract obstruction is gradual or of later onset, urine production is unaffected as long as the compliance of the collecting system can adapt to the increased urinary volume. If the obstruction continues, there is increased peristalsis, decreased compliance and hypertrophy of the collecting system. Eventually a renal affect from obstruction is demonstrated by a reduction in growth and an increase in fibrosis. If the obstruction occurs early, small dysplastic kidneys result without the adaptive processes outlined above3,19. When the obstruction is unilateral and occurs early enough in gestation, there is compensatory hypertrophy of the contralateral kidney23.
Possible etiologies of a hydroureter (Fig. 7) include a megaureter, ureterocele, severe reflux, vesico-ureteral obstruction, and posterior urethral valves.
A megaureter is due to aperistalsis in the distal ureter. The incidence of primary megaureter is 1/6,500 livebirths. 25% of cases are bilateral. 16% of cases have additional anomalies, primarily within the urinary tract. Pelvic kidneys, vesicoureteral reflux and UPJ obstruction have all been described with megaureter3. Spontaneous resolution during the neonatal period has been reported1,24.
A ureterocele (Fig. 8) is a cystic dilatation of the distal intravesical portion of the ureter. Usually the ureterocele is at the orifice draining the upper pole of a duplex kidney. The severity of the obstruction by the ureterocele determines the extent of ureteral and renal obstruction. In some cases, the obstruction can result in renal dysplasia of the lower pole of the kidney.
Vesicoureteral reflux (VUR) is graded as outlined on Table II25. Only grade 3 or grade 4 reflux results in hydroureter. Spontaneous resolution of VUR occurs in 69.1% with grade I, 55.7% with grade II, and 49.1% of patients with grade III26. Pyelectasis, therefore, has a poor sensitivity for the detection of reflux. Bladder dilatation may be a transient finding with severe reflux and is, therefore, sometimes confused with early posterior urethral valves. VUR is associated with other urinary malformations, including unilateral renal agenesis, multicystic kidneys and posterior urethral valves3. VUR occurs in up to 46% of asymptomatic siblings of children with clinically confirmed reflux27. Vesicoureteral reflux (VUR) is graded as outlined on Table II25. Only grade 3 or grade 4 reflux results in hydroureter. Spontaneous resolution of VUR occurs in 69.1% with grade I, 55.7% with grade II, and 49.1% of patients with grade III26. Pyelectasis, therefore, has a poor sensitivity for the detection of reflux. Bladder dilatation may be a transient finding with severe reflux and is, therefore, sometimes confused with early posterior urethral valves. VUR is associated with other urinary malformations, including unilateral renal agenesis, multicystic kidneys and posterior urethral valves3. VUR occurs in up to 46% of asymptomatic siblings of children with clinically confirmed reflux27.
|I||Reflux into non-dilated ureter|
|II||Reflux into kidney without ureteral dilatation|
|III||Mild/moderate ureteral dilatation, renal calyces with minimal blunting|
|IV||Dilatation renal pelvis with moderate ureteral tortuosity|
|V||Marked urteral dilatation and tortuosity; dilated calyces, loss of papillary impressions|
|Derived from Lebowitz RL et al. Pediatr Radiol 1985;15:105.|
Bladder outlet obstruction is caused by stenosis, atresia, or a web across the distal urethra. The earlier the diagnosis is made, the more likely it is due to atresia28. A distended proximal urethra (Fig. 9) at the site of obstruction is specific for posterior urethral valves, but is not present in every case. With progressive obstruction the bladder wall thickens to > 3 mm (Fig. 10). In cases of a posterior urethral web, the increasing bladder pressure required to move urine past the web will, in some cases, rupture the web, resulting in a spontaneous cure of the obstruction.
In males, posterior urethral valves is the most common cause of bladder outlet obstruction. However, in females a persistent cloaca and other complex genitourinary anomalies are more frequently responsible for lower level urinary tract obstruction29.
An occasional finding associated with bladder outlet obstruction is urinary ascites secondary to bladder disruption30. While this is an indication of significant bladder pressure, the reduction of urinary tract pressure may serve to protect remaining renal function. The formation of a urinoma (Fig. 11) is also due to a disruption of the urinary tract in the retroperitoneal space30. Since pressure on the kidney persists due the limited space within the urinoma, renal function will continue to be compromised.
Once a fetal uropathy has been identified sonographically, management and prognosis are the primary concerns of both the healthcare provider and patient. The upper and middle uropathies may be either unilateral or bilateral. With unilateral lesions, as long as contra-lateral function is preserved, the outlook is generally excellent. When both kidneys are affected by a uropathy, the possibility of in utero therapy and/or timed delivery must be entertained.
A thorough fetal anatomic survey looking for associated congenital anomalies is mandatory before developing a management plan for a diagnosed uropathy31,32.
A decision regarding fetal karyotyping must be individualized. The reported rate of aneuploidy with LUTO is around 5%33. As the number of detectable anomalies increases, so does the risk of a karyotypic abnormality31. However, whenever in utero therapy is entertained, karyotyping would seem advisable, as part of a complete evaluation.
Fetal renal function cannot be directly assessed. Since creatinine and uric acid cross the placenta and correlate with maternal concentrations, an assessment of renal function from fetal blood is unreliable. An evaluation of the potential long-term effects of a fetal uropathy utilizes the sonographic assessment of the degree of obstruction, the architectural appearance of the renal parenchyma, amniotic fluid volume and, in isolated cases, fetal urinalysis.
Bilateral renal hyperechogenicity and small cortical cysts are indicative of end-stage renal disease (Fig. 12). Since the progression of renal compromise is on a continuum, the presence of these sonographic markers has a high positive predictive value, but poor sensitivity, for detecting fetal renal failure34. Kidneys with a length > 95th centile for gestational age that are not echogenic have a better prognosis32.
Amniotic fluid volume is a reflection of total fetal urinary output. Serial amniotic fluid indices can, therefore, assess the progression of renal compromise. Anhydramnios, when 2nd trimester normal amniotic fluid has been previously documented, suggests anuria secondary to renal failure.
While the above sonographic findings correlate with poor postnatal renal function (serum creatinine = 1.2 mg/dl), the relatively wide confidence intervals of any one parameter limits the application of the information in individual cases35. For example, renal dysplasia may be irreversible by the time oligohydramnios is apparent33.
Prematurity and pulmonary hypoplasia are the principle causes of mortality with LUTO. 95% mortality rates have been reported with early 2nd trimester oligohydramnios and uretheral obstruction33.
A sampling of fetal urine is reserved for cases of suspected severe outlet obstruction. A normal comparison group has been derived from either normal fetuses prior to termination36, or fetuses with an obstruction who were subsequently found to have normal renal function as a neonate37.
Indices of tubular function undergo significant changes as gestational age advances. Fetal urine is isotonic to plasma at less than 20 weeks' gestation. For example, at 16 weeks' gestation a normal urinary sodium approaches 120 mml/L. It is only after approximately 22 weeks' gestation that a urinary sodium of = 100 mEq/L is considered indicative of poor renal tubular function. Chloride concentrations of > 90 mEq/L and osmolality of > 210 mOsm/L are additional urinary findings associated with poor renal function33.
Fetal serum ?-2 microglobulin levels (an index of glomerular filtration rate) are independent of gestational age. A urinary ?-2 microglobulin > 13 mg/l predicts perinatal death and a level of > 2 mg/l is indicative of postnatal renal failure . Fetuses with a normal urinary sodium, but an elevated beta 2 mircroglobulin are at increased risk for subsequent neonatal renal failure. There is neither an individual analyte, or combination of analytes with a high sensitivity and specifity for detecting poor neonatal renal outcome34,38.
Three sequential fetal urinary samples should be obtained at 48-72 hour intervals. The 1st sample empties the sequestered urine from the bladder and the 2nd sample collects urine from the upper urinary tract. The final sample that is used for analysis reflects urine that has been recently produced by the kidneys. Since vesicourethral reflux may be more severe on one side, the extent of renal damage may also vary. There have been reports of unilateral renal dysplasia on one side with a normal functioning kidney on the other side. Hence, in cases where the kidneys appear architecturally dissimilar, renal pelvic sampling has been proposed38.
Experimental data from the fetal lamb model suggests that bladder shunting in cases of outlet obstruction can prevent the onset of renal dysplasia39. Initial attempts to resolve LUTO by open fetal cystostomy were frought with complications and soon abandoned in favor of vesico-amniotic shunting (Fig. 13).
Morris and co-workers40 published a protocol-driven systematic review that could not show any benefit of antenatal intervention for preserving normal renal function. While antenatal bladder drainage may improve perinatal survival, there is also a high risk of poor postnatal renal function. After a successful vesico-amniotic shunt, 44% of infants in one study had acceptable renal function and 34% required a renal transplant33. Hence, the efficacy of this approach has not been proven in humans41. Displacement of a vesico-amniotic shunt occurs in 40% of cases33.
Fetal procedural morbidity, initiation of pre-term labor, and the potential of fetal demise, mandates that strict guidelines must be followed to ensure that this procedure is only offered in appropriate cases.
The percutaneous shunting in lower urinary tract obstructin (PLUTO) study is a randomized controlled trial comparing in-utero vesico-amniotic shunting with conservative management. Recruitment for this study is closed and the data is being evaluated. Hopefully, the results of the study will provide appropriate guidance for the management of LUTO42.
More recently, fetal cystoscopy has been introduced in an attempt to improve upon the varying success rates reported with vesico-amniotic shunting associated with catheter dislodgement and clogging. In this technique, an endoscope is introduced into the fetal bladder and directed toward the bladder neck and dilated proximal urethra. Laser fulguration of the valves is performed, permitting the egress of urine through the urethra43. Because of the relatively small number of cases to date, a comparison of this procedure with vesico-amniotic shunting cannot, yet, be performed40.
Dilatation of the penile urethra (Fig. 14) results in a functional obstruction of the lower urinary tract. Congenital megalourethra is due to a deficiency of the corpus cavernosum and/or spongiosum; this is a rare anomaly with only 80 cases reported in the English literature by 200245. Since the urethra lacks support, there is urinary stasis during micturation. Megacystis, bilateral hydroureter, and bilateral hydronephrosis may result. Postnatal surgical correction is possible44.
Congenital megalourethra is associated with other genitourinary anomalies, including reflux, renal agenesis and prune belly syndrome45.
Obstructive abnormalities of the urinary tract are the most common anomalies detected on an antenatal ultrasound. Urine production begins at 8 weeks' menstrual age and the earliest detection of obstruction is between 10 and 14 weeks' gestation. The anatomic evolution of the urinary tract over the 1st and 2nd trimesters may result in a temporary obstruction. A systematic prenatal evaluation can result in, not only a correct diagnosis, but also an appropriate managements scheme. In the more severe cases of bilateral obstruction, pre and postnatal evaluation should be individualized in order to optimize long-term renal function.
1 Voucher = 1 CME Credit
|10 or More||$9.50 each*|
Buy 10 or more credits and get the best pricing around. If you don't need them all now they'll be waiting for you later because they never expire.
Once purchased, your CME credits are available at any time in your Online CME Control Panel. Just log back into your account.
"I have recommended your site to a lot of people. It's easy to use and very reasonable pricewise."
Shahla Iloulian, RDMS